In carriers of PALB2 PGV, risk is described as: (i) an absolute risk of BC ranging from 40 to 60%; (ii) a 10% absolute risk of contralateral BC; (iii) a 0.9% absolute risk of male BC; and (iv) an absolute risk of ovarian cancer ranging from 3 to 5%. Here, PALB2 is linked to ovarian cancer.